Zealand Pharma A/S
http://www.zealandpharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Zealand Pharma A/S
Bigger Money: Private Equity Grabs European VC
Deals show large investors’ appetite for early-stage biotech, but can VC and PE rub along?
Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
Nkarta Unveils Early But Promising Data For CAR-NK Therapies In AML, NHL
NKX101 in acute myeloid leukemia and NKX019 in non-Hodgkin’s lymphoma showed high complete response rates, but without the toxicity associated with CAR-Ts.
Finance Watch: Blackstone Closes $1.6bn Fund To Back Commercial-Stage Companies
Public Company Edition: Blackstone Life Sciences Yield will finance approved products, while the firm’s prior fund supports late-stage programs. Also, Coeptis will merge with a SPAC, Bausch + Lomb secured post-IPO debt, and BioXcel revealed a $260m financing and new subsidiary.
Company Information
- Industry
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Encycle Therapeutics, Inc.
- Valeritas Holdings, Inc.